Pfizer Independent Medical Education
Request for Proposals
Improving Care for Patients with Hodgkin and Non-Hodgkin’s Lymphoma
Competitive Grant Program – Pfizer Internal Review Process

Overview
This competitive program seeks to provide educational grants to support continuing education projects focused on the evolving treatment landscape for patients with Hodgkin, T-Cell, and Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).

Geographic Scope/Location of Project
United States

Project Types and Area of Interest
Applicants are encouraged to identify and address the educational needs, barriers, and gaps for patients with Hodgkin Lymphoma, T-Cell Lymphoma, and R/R DLBCL relating to treatments, management of adverse events, and long-term outcomes.

Proposed activities should focus on increasing clinicians’ knowledge, confidence, competence, and practice changes in caring for patients. This may include interactive learning, case-based learning, workshops, tumor boards, digital platforms, building communities of practice, and other live programs.

Key Milestones
• Application submission deadline: June 26th 2024
• Anticipated decision notification date: July 31st 2024
• Anticipated project start date: September 2024

Funding Range and Project Length
Individual projects requesting up to $200,000 will be considered. The estimated total available budget related to this RFP is $1,500,000.

Expected typical grant range: $20,000 to $200,000. For example, smaller, local, or single healthcare institution projects should be at the lower end of this range.

Project length should be approximately 12-15 months.
I. Eligibility

Geographic Scope/Location of Project:
- United States

Applicant Eligibility Criteria
- Only organizations are eligible to receive grants, not individuals or medical practice groups.
- The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- If the project involves multiple departments within an institution and/or between different institutions/organizations/associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- The applicant must be the project/program lead or an authorized designee of such individual (e.g., project/program lead’s grant coordinator).
- The project/program lead must be an employee or contractor of the requesting organization.
- Requesting organization must be accredited.
- For projects offering continuing education credit, the requesting organization must be accredited.

II. Requirements

Date RFP Issued:
- May 2nd, 2024

Clinical Area:
- Oncology-Hematology: Hodgkin Lymphoma, T-Cell Lymphoma, and Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
General Area of Interest for this RFP:

The goal of this RFP is to support education targeting community hematologists, oncologists, pharmacists, nurse practitioners and physician assistants working in the oncology setting caring for patients with Hodgkin Lymphoma, T-Cell Lymphoma, and R/R DLBCL relating to treatments, management of adverse events, and long-term outcomes.

Projects that will be considered for Pfizer support will focus on addressing the educational needs related to one or more of the following diseases:

1. **Hodgkin Lymphoma:**
   - long-term clinical efficacy and safety profile of existing 1L treatment options, and sequencing for optimal patient outcomes.
   - different treatment options for, and survivorship of, the pediatric and AYA patient population.
   - early identification of AEs and management/resolution strategies across multiple lines of therapy, including monotherapy and combo therapy.
   - how improved long-term outcomes for patients can translate into reduction in holistic cost of care including productivity and indirect costs.

2. **T-Cell:**
   - long-term clinical efficacy and safety profile of therapeutic options in the 1L treatment of PTCL.
   - diagnostic, prognostic, and treatment applications of CD30 expression in PTCL subtypes.
   - Support team-based learning and communication to improve knowledge and competence of the accuracy of lymphoma sub-classification and relevance of CD30 expression in therapeutic decision making.

3. **R/R DLBCL**
   - Diagnostic and prognostic biomarkers for DLBCL, and utility in guiding treatment decision-making and patient management.
   - Treatment options for patients with relapsed/refractory DLBCL, taking into consideration efficacy, safety, and patient-specific factors, to optimize patient outcomes.
   - Management of adverse events associated with novel therapies used in the treatment of patients with relapsed/refractory.
   - DLBCL Mechanisms of drug-resistance/loss of response with emerging treatments.

Proposed activities should focus on increasing clinicians’ knowledge, confidence, competence, and practice changes in caring for patients. Activity formats that will be considered under this RFP include interactive learning, case-based learning, workshops, tumor boards, digital platforms, and projects to build communities of practice.

**Target Audience:**
- Academic & Community hematologists/oncologists, oncology nurses, oncology NP/PAs, oncology pharmacists
**Expected Approximate Monetary Range of Grant Applications:**
- Individual projects requesting up to $200,000 will be considered.
- Expected typical grant range: $20,000 to $200,000. For example, smaller, local, or single healthcare institution projects should be at the lower end of this range.
- Projects greater than $200,000 may be considered for exceptional proposals with detailed budget justification.
- The estimated total available budget related to this RFP is $1,500,000.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

**Key Dates:**
- RFP release date: **May 2\textsuperscript{nd} 2024**
- Grant Application due date: **June 26\textsuperscript{th} 2024**
  Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
- Anticipated Grant Award Notification Date: **July 31\textsuperscript{st}, 2024**
- Grants will be distributed following a fully executed agreement.
- Anticipated approximate Project Start and End Dates: September 2024 to December 2025

**How to Submit:**
Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.
- Please go to [www.cybergrants.com/pfizer/knowledge](http://www.cybergrants.com/pfizer/knowledge) and sign in. First-time users should click “Create your password”. [Note: there are individual portals for each grant application type. Please be sure to use the URL above.]
- Click the “Start A New Knowledge Gap Application” button.
- In the application:
  - For the question “What type of request are you submitting?” select Response to a Request for Proposal (RFP)
  - For the question “Are you replying to a Request for Proposal (RFP) as part of the Competitive Grant Program?” select Yes
  - Select the following Competitive Grant Program Name: **2024 ONC US Hodgkin and NHL MedEd**
  - Select the following Primary Area of Interest: Oncology - Hematologic - KG
- Requirements for submission:
  Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

**Questions:**
- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Don Rodriguez ([Don.Rodriguez@pfizer.com](mailto:Don.Rodriguez@pfizer.com)), with the subject line “2024 ONC Hodgkin and NHL MedEd.”
Grant Agreements:
- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click here to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.

Review and Approval Process:
- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

Mechanism by which Applicants will be Notified:
- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

References:
- Bibliography of relevant references.

About Pfizer Global Medical Grants
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Appendix

General RFP Submission Requirements
Applications will be accepted via the online portal listed in the How to Submit section. Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. When uploading your Project Proposal please ensure it addresses the following sections:

Goals and Objectives
• Briefly state the overall goal of the project.
• List the objectives you plan to meet with your project, in terms of learning and expected outcomes.

Needs Assessment for the Project
• Include a description of your organization’s needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.

Target Audience
• Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

Project Design and Methods
• Describe the planned project, the educational approach, and the way the planned methods address the established need.

Innovation
• Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.

Evaluation and Outcomes
• In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.

Dissemination Plan
• Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.

Anticipated Project Timeline
• Provide an anticipated timeline for your project including project start/end dates.
Additional Information
- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.

Organization Detail
- Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.

Budget Detail
- Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application.
- While estimating your budget please keep the following items in mind:
  - Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic assets (prescription or non-prescription).
  - Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer. Please click here for details. General organizational running costs such as legal fees, insurance, heating, and lighting etc. should be included in an Institutional Overhead (if required). These costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.